Please wait while the transcript is being prepared...
0:00
A good day to everyone,
and welcome to a new episode
of the Henry Stewart
talk series.
My name is Ulf Jensen-Kondering
and I'm based at
the Department of
Neuroradiology at
the University Hospital
Schleswig Holstein
in Lubeck, Germany.
The topic of my talk is
cerebral spinal fluid and
blood biomarkers in cerebral
amyloid angiopathy.
I put blood biomarkers
in parenthesis,
because the talk
really is mainly about
cerebral spinal fluid
biomarkers, as you will see.
0:32
In this talk, I will introduce
you to the diagnostic problems
that we encounter when we deal
with cerebral
amyloid angiopathy.
I will introduce mainly cerebral
spinal fluid biomarkers.
In the end, you should
have an idea about when
cerebral spinal fluid
biomarkers are helpful.
What biomarkers are important,
and which deserve
further attention?
0:55
As of today, the diagnosis of
cerebral amyloid
angiopathy is made
using the Boston criteria 2.0.
They incorporate a number of
MRI imaging markers and
clinical information.
They will be discussed in
great detail elsewhere.
There are, however, a number of
scenarios when additional
markers or information are
needed to obtain a
diagnosis or to have
a useful diagnosis at all.
1:24
To give you an idea on
the diagnostic problems,
let's have a look at the
MRI of this patient.
In this scenario, two
imaging hallmarks
of cerebral amyloid
angiopathy are present.
Namely, multiple lobar,
cerebral microbleeds
highlighted by the circles,
and a very specific marker
of cerebral amyloid angiopathy,
cortical superficial siderosis
highlighted by the arrows.
Depending on the
clinical presentation,
the sensitivity of the
Boston Criteria 2.0 ranges
between 55 and 95% with
overall moderate sensitivity
and specificity.
It is recognized that the
sensitivity is low in patients
without intracranial
hemorrhages and
in a non hospital setting.
